Stock Ratings / Health Care / INMD / earnings

CBLL (45) CNMD (62) CV (44) TMDX (69) ⌘ Pro Terminal →

InMode Ltd. (INMD) Next Earnings Date & Expected ±3.2% Move

Q: Is INMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, InMode Ltd. (NASDAQ: INMD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $13.51 (+1.05% 1D, market cap $776.6M). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, INMD ranks #57 in composite RQD confidence.

Q: How does INMD compare to CBLL and CNMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), INMD carries a Roarable B (74/100 RQD), trailing P/E of N/A, gross margin of 78.5%, and ROIC of 17.7%. By comparison, CBLL (CeriBell Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B) and CNMD (CONMED Corporation) posts a C grade (62/100 RQD, P/E 28.9x, ROIC 7.8%, cap $1.36B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for INMD?

Per INMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001742692), InMode Ltd. generated $370.5M in revenue (-6.2% YoY), $0 in net income, and $84.3M in free cash flow against $766.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (79% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is INMD trading relative to its 50-day, 200-day, and 52-week technical levels?

INMD last traded at $13.51 (+1.05% on volume of 370,624 shares), positioning the stock -6.05% below its 50-day simple moving average ($14.38) and -5.72% below its 200-day simple moving average ($14.33). Across its 52-week range of $12.72 to $16.67, INMD sits at the 20.0% percentile with a 14-day RSI of 24.2 (OVERSOLD (<32)) and an implied next-earnings move of ±3.2% ($13.08 to $13.94).

Q: When is INMD's next earnings date?

Based on SEC filing cadence, InMode Ltd. (INMD)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is INMD stock expected to move on earnings?

Volatility modeling currently projects a ±3.2% event move for INMD, spanning a range between $13.08 and $13.94.

$13.51 +1.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.57

InMode Ltd. (INMD) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (79% profit margin, 18% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate) →

ROARABLE B • BUY Cap $776.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $13.57 (+0.43%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 22.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B- · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INMD)Realized 20D OHLCV Swing Band: ±3.2%

Deterministic 5-Pillar Attribution (74/100 Composite)

🔍 WHY INMD SCORES 74/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (22% of score)

Altman Z-Score 9.20 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+16/20 pts (22% of score)

FRED Regime × Technicals: 20% of 52W Range • RSI-14 at 24.2 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning12/20 pts (-8 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-8 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade A$14.21-0.4% Next Q

Q2 (-2Q)

Grade A-$14.16-1.3% Next Q

Q3 (-1Q)

Grade B+$13.97-3.3% Next Q

Current

Grade B$13.51+7.3% Hist 90D α

Trajectory: A (82) → B (74)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the INMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 74/100 (B) score, INMD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 76.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($14.38) or 200D SMA ($14.33) invalidates the momentum regime and cuts Target Base ($14.48) toward Bear Floor ($11.08).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 74%NO 26%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±3.2% Swing Band

±$0.43 Expected Swing

MODEL EARNINGS SETUP GAUGE

INMD Quantitative Pre-Earnings Setup: 74/100

Trailing EPS: $4.25 • YoY Revenue Growth: -6.2%

Model Bullish Setup (74/100)Model Risk Weight (26/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$370.5M	$0	$84.3M	78.5%
FY 2024	2024-12-31	$394.8M	$0	$132.0M	80.3%
FY 2023	2023-12-31	$492.0M	$197.9M	$176.8M	78.5%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating INMD & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on INMD
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.63%▼ SUPPORT BREAKDOWN

2026-10-30O $13.60H $13.60L $13.19C $13.51VOL 439.8K

RES: $14.58SUP: $14.00SMA50: $14.38SMA200: $14.33

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INMD Butterfly Map → + Track INMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-8.3%/yr Implied 5Y Growth

vs. -6.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INMD)

Health Care Rank #57 of 1016 ⚔️ CBLL vs INMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INMD vs. CBLL, CNMD, CV, TMDX)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, InMode Ltd. (INMD) ranks #57 by composite RQD confidence (74/100, grade B) and #390 by equity capitalization ($776.6M). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. INMD currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INMD ACTIVE InMode Ltd.	B	74/100	—	78.5%	17.7%	+1.05%	$776.6M	Benchmark Subject
CBLL CeriBell Inc.	D	45/100	—	87.9%	-35.0%	+2.20%	$1.07B	/cbll-vs-inmd →
CNMD CONMED Corporation	C	62/100	28.9x	54.6%	7.8%	-0.09%	$1.36B	/cnmd-vs-inmd →
CV CapsoVision Inc.	D	44/100	—	52.9%	-35.0%	-1.70%	$369.2M	/cv-vs-inmd →
TMDX TransMedics Group Inc.	C+	69/100	12.2x	59.9%	18.1%	+0.33%	$2.33B	/tmdx-vs-inmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001742692

In its most recent audited fiscal period (FY2025, filed 2025-12-31), InMode Ltd. (INMD) reported GAAP revenue of $370.5M (-6.2% vs. FY2024 revenue of $394.8M , and -24.7% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $85.3M, and free cash flow of $84.3M (-36.1% YoY). On the balance sheet, INMD closed FY2025 with $766.4M in total assets against $0 in total debt (Altman Z-Score: 9.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$370.5M	$0	$85.3M	$84.3M	$766.4M	—
FY2024 (FY)	2024-12-31	$394.8M	$0	$132.7M	$132.0M	$785.7M	—
FY2023 (FY)	2023-12-31	$492.0M	$197.9M	$176.8M	$176.8M	—	—

3. INMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, InMode Ltd. (NASDAQ: INMD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $13.51 (+1.05% 1D, market cap $776.6M). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, INMD ranks #57 in composite RQD confidence.

How does INMD compare to CBLL and CNMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), INMD carries a Roarable B (74/100 RQD), trailing P/E of N/A, gross margin of 78.5%, and ROIC of 17.7%. By comparison, CBLL (CeriBell Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B) and CNMD (CONMED Corporation) posts a C grade (62/100 RQD, P/E 28.9x, ROIC 7.8%, cap $1.36B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INMD?

Per INMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001742692), InMode Ltd. generated $370.5M in revenue (-6.2% YoY), $0 in net income, and $84.3M in free cash flow against $766.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (79% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INMD trading relative to its 50-day, 200-day, and 52-week technical levels?

INMD last traded at $13.51 (+1.05% on volume of 370,624 shares), positioning the stock -6.05% below its 50-day simple moving average ($14.38) and -5.72% below its 200-day simple moving average ($14.33). Across its 52-week range of $12.72 to $16.67, INMD sits at the 20.0% percentile with a 14-day RSI of 24.2 (OVERSOLD (<32)) and an implied next-earnings move of ±3.2% ($13.08 to $13.94).

INMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is INMD's next earnings date?

Based on SEC filing cadence, InMode Ltd. (INMD)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is INMD stock expected to move on earnings?

Volatility modeling currently projects a ±3.2% event move for INMD, spanning a range between $13.08 and $13.94.

Direct Sub-Reports: INMD RQD Cockpit INMD 12M Forecast INMD Earnings & Move INMD Dividends & DRIP INMD Insiders & 13F INMD Whale Options INMD Profit Sankey INMD News & Why